Get Adobe Flash player

ALLELIC CONDITION OF GENE PPAR-GAMMA2, ACE IN PATIENTS WITH ARTERIAL HYPERTENSION AND ABDOMINAL OBESITY

Authors: Sokolenko A.A., Sydorchuk L.P., Sokolenko M.O.

Pages: s1-s12

Abstract

  

Introduction. Abdominal obesity (AO) is one of the major independent risk factors of arterial hypertension (AH). AH and AO are multifactorial polygenic diseases. The peroxisome proliferator activated by gamma 2 receptor (PPAR-g2) plays a pivotal role in the lipid metabolism. PPAR receptors modulate the activity of the renin-angiotensin-aldosterone system (RAAS) through transcriptional control of the synthesis of renin, angiotensin, angiotensin-converting enzyme (ACE) and angiotensin II receptor type 1, linking biological effects of RAAS and PPARs. Therefore, the study of genes polymorphism PPAR-γ2 receptor and ACE allows us to explore in detail their role in the pathogenesis of AH and AO.

Our aim was to analyze the frequency of alleles and genotypes of Pro12Ala polymorphism of PPAR--g2 gene (rs1801282) and I/D polymorphism of ACE gene (rs4646994) in patients with essential AH (EAH) combined with overweight or AO.

Material and Methods. 110 screened patients with EAH I–III stages participated in a prospective study: 56.4 % women, 43.6 % men; mean age – 53.3 ± 6.05 years. Among them we revealed EAH I in 22.7 % cases, EAH II – in 45.45 %, EAG III – 31.8 %; overweight persons – 38.2 %, with AO – 53.6 %. The control group included 50 healthy individuals. Alleles of polymorphic locus were studied by polymerase chain reaction based method. Statistical processing was performed usingthe Statistica® 7.0 software. The differences were considered significant at p < 0.05.

Results. The DD-genotype of ACE gene in EAH patients is observed in 39.1 % cases, which is 2.2 times more than in the control group. In patients with EAH dominated "unfavorable" D allele. DD-genotype is associated with a greater frequency of concomitant coronary artery disease, cerebrovascular disease, left ventricle hypertrophy (LVH) in women, higher levels of systolic blood pressure (SBP), and obliterative arterial disease of lower extremities (OADVE).

ProPro-genotype of PPAR-g2 gene was found in 63.6 % cases, which generally does not differ from the control group (60.0 %). Among patients with EAH dominates Pro-allele by 3.9 times (79.5 % vs. 20.4 % Ala-allele carriers), likewise in the control group by 3.5 times (78.0 % vs. 22.0 %), respectively. ProPro-genotype in patients with EAH associated with significantly more frequent cases of diabetes mellitus type 2, AO, LVH in men, OADVE, inherited AO, higher SBP, diastolic BP, and waist circumferences in men. In patients with EAH I dominates I-allele of ACE gene by 3.8 and 3.23 times and ProPro-genotype of PPAR-g2 gene over AlaAla-genotype by 4.67 and 14 times. Exclusively D-allele and Pro-allele carriers were available among patients with EAH III stage. In patients with EAH with normal body weight and AO 1st degree II genotype prevails over DD-option by 2 and 4 times, respectively. In those with overweight, AO 2nd degree the ProPro-genotype dominated the AlaAla-genotype by 12–17 times; among those with overweight available only D-allele carriers; in patients with EAH AO 3rd degree – there are only ProPro-carriers.

Conclusion. DD-genotype or D-allele of ACE gene is a risk factor for EAH II and III stages (OR = 2.33–4.45, p ≤ 0.014–0.013), excess body weight (OR = 4.10–4.45, p < 0.001), AO (OR = 4.45, p < 0.001) with the lowest probability of EAH I stage (OR = 0.22, p = 0.007).

Key words: arterial hypertension, abdominal obesity, АСЕ gene (I/D), PPAR-g2 (Pro12Ala).

This email address is being protected from spambots. You need JavaScript enabled to view it. 

The full text

To view the full text

References

 

  1. KovalenkoVM, TalayevaTV, KozliukAS.[Metabolic syndrome: mechanisms, value as a predictor of cardiovascular diseases, approaches in diagnosis and treatment]. Ukr J 2013;5:80–87.
  2. Mitchenko OІ, Romanov VYu, Kulyk OYu, Shkroba GO.[Leptin resistance in patients with essential hypertension and metabolic syndrome].Ukr J2014;2:31–35.
  3. Ataman AV, Garbusova VY, Ataman YuA, Matlaj OI, Obuchova OA. Investigation of the MGP promoter and exon 4 polymorphisms in patients with ischemic stroke in the Ukrainian population. J Cell and Molecular Biology. 2012;10(1):19–26.
  4. Sydorchuk LP, Gaborets IY, Sydorchuk AR, Ursulyak YuV, Sokolenko AA, Ivashchuk SI et al. Combined effects of ACE (I/D) and eNOS (894T>G) genes polymorphism in patients with arterial hypertension in the realization of molecular mechanisms of left ventricular hypertrophy. The New Armenian Medical J. 2013;7(2):44–54.
  5. SydorchukLP, GaboretsIY, SydorchukAR, BukachOP, SokolenkoAA, UrsuliakJV, etal. Value of angiotensin-cenzyme and mnitrogen in pathogenesis of myocardium remodeling depending on genes' ppatients with arterial h Intern J of Collabor Research on Int Med & Public Health. 2013;5(3):168
  6. SydorchukLP, AmosovaKM. Influencepharmacogeneticallydeterminedtreatmentparametersperipheralhemodynamicsinpatientswitharterialhypertension.TheNewArmenianMedicalJ. 2011;5(2):35–43.
  7. Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X. Distribution of C-reactive protein in its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol. 2007;49(17):1798–1805.
  8. Tsuchida A, Yamauchi T, Takekawa S. Hada Y, Ito Y, Maki T, Kadowaki T. Peroxisome proliferator-activated receptor (PPRAα) activation increases adiponectin receptor and reduces obesity-related inflammation in adipose tissue. Comparison of activation of PPRAα, γ, and their combination. Diabetes. 2005;54(12):3358–3370.
  9. Roszer T, Ricote M. PPARs in the renal regulation of systemic blood p PPAR Res. 2010;2010:698730.
  10. Vergotine Z, Yako YY, Kengne AP, ErasmusRT, Matsha TE.Proliferator-activated receptor gamma Pro12Ala interacts with the insulin receptor substrate 1 Gly972Arg and increase the risk of insulin resistance and diabetes in the mixed ancestry population from South Africa. BMC Genet 2014;15:
  11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, etal.2013 ESC/ESH guideline for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertension. 2013;31(10):1281–1357.
  12. Ministry of Health of Ukraine Order № 384 dated 24.05.2012 [Guidelines and clinical protocols of medical care "Hypertension".On approval and implementation of medical and technical documents on standardization of medical care in patients with arterial hypertension]. Kyiv: Ministry of Health Crae of Ukraine Publ., 2012.
  13. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA,etal. 2013 AHA/ACC/TOS guideline for the management of verweight and besity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.2014;129(25 Suppl. 2):S102–38.
  14. Entrez Gene. Sequence analysis 2014. National Center for Biotechnology Information. Retrieved from: http://www.ncbi.nlm.nih.gov/
  15. Sekerli E, Katsanidis D, Papadopoulou V, Makedou A, Vavatsi N, Gatzola M.Angiotensin-I converting enzyme gene and I/D polymorphism distribution in the Greek population and a comparison with other European populations. J Genetics. 2008;87(1):91–93.
  16. Topal NP, Ozben B, Hancer VS, Tanrikulu AM, Diz-Kucukkaya R, Fak AS, Basaran Y, Yesildag O. Polymorphisms of the angiotensin-converting enzyme and angiotensinogen gene in patients with atrial fibrillation. J RAAS. 2011;12(4):549–556.
  17. Kaydashev IP, Rasine AM, Shlykova OA, Gorbas IM, Smirnov IP, Petrushov AV, etal. Frequency Pro12Ala PPARγ2 gene polymorphism in Ukrainian population and its possible connection with the development of metabolic syndrome.Cytology and Genetics. 2007;5:43–47.
  18. Stumvoll M, Haring H.The peroxisome proliferator-activated receptor-γ2 Pro12Ala p.Diabetes. 2002;51(8):2341234.
  19. Pinterova D, Cerna M, Kolostova K, NovotaP, Cimburova M, Romzova M, Kubena A, Andel M.The frequency of alleles of the Pro12Ala polymorphism in PPARgamma2 is different between healthy controls and patients with type 2 diabetes. Folia Biol (Praha). 2004;50(5):1536.

 

STUDY OF ENOS GENE EXPRESSION IN PLACENTAL TISSUE DURING IRON DEFICIENCY ANEMIA

Authors: Ancheva I.A. 

Pages: s13-s19

Abstract


Introduction. One ofthe mosturgent problemsof modern obstetricsis the occurrenceof iron deficiencyin pregnant women. The experts assess its prevalence in 20–30 % ofcasesin economicallydeveloped countriesand50–80 % – in developing countries.InUkrainein the recent years,the incidenceof iron deficiency anemia during pregnancy increased from15.0 to 22.6 %. The interest ofresearchersto the problemof IDAdue to the factthat inthispathological conditionincidenceof preeclampsia,preterm labor, polyhydramnios, prematurerupture of membranes,weakness of laborforces and otherpregnancy complicationssignificantly increased.According toexperts, theincrease in the amountof blood lossduring laboris in 10 % ofpregnant women withIDA.This populationof pregnant womenhasalsopostpartumseptic complicationsandhypogalactia. Iron deficiency significantly worsensoverall condition of mother and fetus.

Our aim was to evaluate the gene expression of eNOS in placental tissue of the pregnant women with iron deficiency anemia.

Material and Methods. Research performed at the maternity hospital № 2 (Odessa), Genetic Laboratories "Nadiaya" and pathomorphological department of State Institution "IPOG NAMSU" (Head, Professor, MD Zadorozhna TD, Kyiv). The study involved 100 women in labor; we took placenta samples from them. Thus, the following clinical groups were designed: group 1 – the placenta samples of women with physiological pregnancy and childbirth (n = 20), group 2 – the placenta samples of pregnant women with a history of anemia (n = 40), group 3 – the placenta of women with placental dysfunction and a history of anemia (n = 40). In addition to the general clinical research methods, we used current clinical protocol approved by the order № 782 dated 29.12.2005 “On approval of clinical protocols for obstetric and gynecological care”, further research was conducted analysis of immunohistochemical expression of endothelial nitric synthase (eNOS) in placental tissue. Age of pregnant women ranged from 20 to 35 years (28.5 ± 2.8 years).

Discussion. As a result the level of eNOS gene expression increased by 1.4 folds in patients with IDA, while the combination of IDA and placental dysfunction eNOS gene expression level reduced by 10 folds. We discuss the adaptive nature of changes in eNOS gene expression in iron deficiency amongst pregnant women. There were compared genetic and phenotypic characteristics of the enzyme activity of endothelial nitric oxide synthase in decidual tissue. When comparing detected changes of eNOS gene expression with the phenotypic manifestations we found that the expression of endothelial nitric oxide synthase in patients with dysfunction of the placenta in the cytoplasm synticia villi and fetal capillary endothelium and vascular decidua reduced, and the presence of a combination of placental dysfunction and iron deficiency anemia occured with the paradoxical increase expression of the enzyme. Thus, inhibition of eNOS gene expression is a reflection of the exhaustion of the adaptive capacity of the organism. This circumstance suggests that routine administration of nitric oxide precursor (L-arginine medication) in women with gestational endoteliopatiyi manifestations may not give the desired effect due to the presence of a genetically determined deficiency of endothelial nitric oxide synthase and its products. Besides, when isolated iron deficiency anemia occurs than changes in eNOS gene expression is less evident.

Key words: iron deficiency anemia, pregnancy, nitric oxide synthase, genetics.

This email address is being protected from spambots. You need JavaScript enabled to view it. 

The full text

To view the full text

References

 

  1. Blackburn S. Maternal, fetal, andneonatal p 4th ed.NY: Saunders; 2012. 768
  2. Salomon C, Kobayashi M, Ashman K, Sobrevia L, Mitchell MD, RiceHypoxia-induced changes in the bioactivity of cytotrophoblast-derived exosomes. PLoS One. 2013;8(11):
  3. Ancheva IA. [Clinical epidemiology of anemia during pregnancy in the Southern Ukraine: retrospective study].Visnyk Problem Biologii i Medytsyny. 2013;2(3):112–114.
  4. O'Farrill-Santoscoy F, O'Farrill-Cadena M, Fragoso-Morales LE. Evaluacion del tratamiento a mujeres embarazadas con anemia ferropenica. Ginecol Obstet Mex. 2013;81(7):377381
  5. Goldman-Wohl D, Yagel S. United we stand not dividing: the syncytiotrophoblast and cell senescence. Placenta. 2014;35(6):341–4.
  6. Zaporozhan VM, Konkov DG, Galich SR, Lutsker OL, inventors;І. Pіrogov Vіnnitsa National Medical Unіversity. Sposib neinvazyvnoi diahnostyky funktsionalnoho stanu endoteliiu pry vahitnosti [The method of non-invasive diagnostics of the functional state of endotelium in the pregnancy]. Ukrainian patent, no. 77984 (2013) A61V 10/00, 2013.
  7. Koskenkorva-Frank TS, Weiss G, KoppenolWH, Burckhardt S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic Biol Med. 2013;65:1174–94.
  8. Petruk AA, Vergara A, Estrin D, Merlino A. Molecular basis of the NO trans influence in quaternary T-state human hemoglobin: a computational study. FEBS Lett. 2013;587(15):2393–8.
  9. ENOS gene. Retrieved from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=NOS3&search=d04b4425441eb1347cc891141f3462f8
  10. Kapustin RV, Arzhanova ON, Polyakova[Vascular tropic signaling molecules expression in the placental tissue samples from puerperae with gestational diabetes mellitus].Molecular Medicine. 2012;5:4549.
  11. Nakaz 782 Prozatverdzhenniaklinichnykhprotokolivzakusherskoitahihienichoidopomohy [Orderno. 782 datedOn approvement of clinical protocols on the obstetrics and gynecology care]. Kyiv: Ministry of Health Care of Ukraine Publ., 2005.
  12. Yau C. R tutorial.Retrived from:http://www.r-tutor.com/r-introduction.

 

АNALYSIS OF THE EFFECT OF BONE MORPHOGENETIC PROTEIN-2 (BMP-2) GENE SER37ALA POLYMORPHISM ON SOME CHARACTERISTICS OF THE ACUTE CORONARY SYNDROME

Authors: Garbuzova V.Yu. 

Pages: s20-s28

Abstract


 

Introduction. BMP-2, like other bone morphogenetic proteins, plays an important role in the development of bone and cartilage, in osteoblast differentiation. As the calcification of the atherosclerotic plaque is an untoward prognostic factor of the acute coronary syndrome, the polymorphism of gene BMP-2 can be associated with the disease progression.

The aim isto establish the association of allelic variants of BMP-2 gene Ser37Ala polymorphism on some characteristics of the acute coronary syndrome (clinical variants, ECG manifestations, development of complications).

Material and Methods. We used venous blood of 118 patients with ACS (22 % women and 78 % men) aged 40 to 73 years (mean age 55.9 ± 0.89 years) hospitalized in the cardiology department of Sumy City Clinical Hospital № 1. The control group consisted of 234 patients. I performed definition of Ser37Ala polymorphism (rs2273073) of BMP-2 gene using PCR with the following restriction fragment length analysis of the allocation of them by electrophoresis in agarose gel. Restriction endonuclease Hpy99I was used for restriction analysis. Statistical analysis was performed by using the software package SPSS-17. Thus, the significance of differences was determined by the χ2-criterion. The value of P < 0.05 was considered as significant.

Results. There isn’t significant difference in the ratio of genotypes (Ser/Ser, Ser/Ala, Ala/Ala) between patients with anginal form of acute coronary syndrome (ACS) and patients with other forms of ACS (аsthmatic, abdominal, arhythmic and painless). It accounted for 51.5; 30.1 and 18.4 % in the group with anginal form of ACS; and 40.0, 46.7 and 13.3 % – in the group with other forms of ACS. Using the χ2-Pearson criterion, it did not reveal association between the Ser37Ala polymorphism of ВМР-2 gene and the clinical variants of ACS (χ= 1.652, Р = 0.438). Analysis of the data about correlation Ser37Ala polymorphism of BMP-2 gene with different clinical variants of ACS showed no association of investigated SNP with different clinical manifestations of this disease (unstable angina, non-Q-myocardial infarction, Q-and QS-myocardial infarction). There is no veracity in the distribution of genotypes considering such risk factors as gender, BMI, hypertension, lipid composition and blood hypercoagulation, diabetes, and obesity. The difference of allelic variants frequency was statistically significant (P = 0.033) in groups with different clinical forms of ACS only in patients, who smoke. Smokers with Ser/Ser genotype were significantly more likely to develop anginal form of ACS. Significant difference in the distribution of patients with unstable angina, non-Q-myocardial infarction, Q-and QS-myocardial infarction was found only in patients with obesity (P = 0.018). I did not find significant difference in the distribution of genotypes between patients with complications and those who have had the disease without complications. However, the association with the development of complications of ACS was for male patients, smokers, patients without DAC and without obesity.

Ambiguity and deficiency of data about relationship Ser37Ala and other polymorphisms of BMP-2 gene with the development of ACS requires further research in this area.

Conclusion: Smoking patients with Ser/Ser genotype BMP-2 gene Ser37Ala polymorphism are significantly more likely to develop anginal form of ACS.

There is significant difference in the distribution of genotypes among individuals with unstable angina, non-Q-myocardial infarction, Q-and QS-myocardial infarction in the group without obesity.

There is a link with the development of complications of ACS for male patients, smokers, patients without atherogenic dislipoproteinemia and without obesity.

Key words: allelic polymorphism, bone morphogenetic protein-2, acute coronary syndrome.

vikgarbuzova@yandex.ru 

The full text

To view the full text

References

 

  1. Urist MR. Bone: formation by autoinduction. Science. 1965;150:893–899.
  2. Urist MR, Strates BS. Bone morphogenic protein. J. Dental. Res. 1971;50(6):1392–1406.
  3. Gosselet FP, Magnaldo T, Culerrier RM, Sarasin A, Ehrhart JC. BMP2 and BMP6 control p57Kip2 expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. Cell. Signal. 2007;19:731–739.
  4. Kang MH, Kim JS, Seo JE, Oh SC,Yoo YA. BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K). Exp Cell Res. 2010;316,(1):24–37.
  5. Langenfeld E, Langenfeld J. Bone mprotein-2 stimulates angiogenesis in developing t Mol Cancer Res. 2004;2:141–149.
  6. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, JonesRH, et al. ACC/AHA guidelinesfor the management of patients with unstable angina and non ST-elevation myocardial infarction: executive summary and recommendations. A report of the american college of cardiology. Circulation. 2000;102:1193–1209.
  7. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, DeFeyter PJ, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809–1840.
  8. Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature.
  9. Styrkarsdottir U, Cazier J-B, Kong A, Rolfsson O, Larsen H, Bjarnadottir E, Johannsdottir V, et al. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol. 2003;11(3):351–360.
  10. Ichikawa S, Johnson ML, Koller DL, Lai D, Xuei X, Edenberg HJ, Hui SL, et al. Polymorphisms in the bone morphogenetic protein 2 (BMP2) gene do not affect bone mineral density in white men or women. Osteoporos Int. 2006;17(4):587–592.
  11. Varanasi SS, Tuck SP, Mastana SS, Dennison E, Cooper C, Vila J, Francis RM, Datta HK. Lack of association of bone morphogenetic protein 2 gene haplotypes with bone mineral density, bone loss or risk of fractures in men. J Osteoporos. 2011;2011:243465.
  12. Freedman BI, Bowden DW, Ziegler JT, Langefeld CD, Lehtinen AB, Rudock ME, Lenchik L, et al. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: The Diabetes Heart Study. J Bone Miner Res. 2009;24(10):1719–1727.

 

CYTOKINES GENES POLYMORPHISM IN PATIENTS WITH HIV INFECTION

Authors: Piddubna A.I., Chemych M.D.

Pages: s29-s37

Abstract


Our aim was to study distribution character of the allelic variants of cytokines genes in HIV-infected Ukrainians.

Data for the study were DNA samples, received from 200 inhabitants of Ukraine: 78 HIV-infected, 22 HIV-negative individuals from the group of high risk of contamination, 100 healthy blood donors. IL-4 (-590C/T), IL-10 (-592C/A) andTNF-α (-308G/A) genes polymorphisms detection was made with the PCR-RLFP method.

By analysis of frequency of IL-4 gene allelic variants, we discovered that homozygotes by the main allel were the dominant variant. Among people with HIV T/T minor gene carriers were 4.5 more often met in comparison with the control group (p < 0.05) that can prove the tendency to association of the mentioned genotype with infection. Distribution of allelic variants of IL-10 gene promoter region in position -592 is characterized by homozygote dominance by the main gene. Among the individuals with HIV A/A minor allel carriers were 3.4 more often than in the control group (p < 0.05). Individuals with A/A genotype were not identified in group of high risk of virus infection. The abovementioned proves the tendency to association of minor allel carrier state with HIV infection. Theoccurrenceofthehomozygouscombinationoftheallelicvariant G/GofthepromoterofTNF-αis provedtoprevailalmosttwofoldovertheoccurrenceofthevariantG/Aamong all groups. High frequency of heterozygote by the main allel was recorded among the individuals with HIV. Thus, G/A genotype frequency in group of HIV-infected people by 2 and 1.5 times exceeded the appropriate indices of group of high risk of infection and comparison group correspondingly (p < 0.05) that points on the tendency to association of the mentioned variant with infection. We concluded that cytokines genes variationsmaycontributetotheacquisitionofHIVinfectionin the Ukrainians andencourages carrying out further populations studies in this sphere of HIV-infection immunogenetics.

Key words: HIV infection, cytokines, allelic polymorphism.

tranki1@mail.ru

The full text

To view the full text

References

 

  1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. WHO Library. 2010. 364 p.
  2. UNAIDS. Progress report 2011: Global HIV/AIDS response. WHO Library. 2011. 229 p.
  3. Cashin K, Roche M, Sterjovski J, Ellett A, Gray LR, Cunningham AL, Ramsland PA, et alAlternative crequirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages. J Virol. 2011;85(20):10699–709.
  4. Gorry PR, Ancuta P. Coreceptors and HIV-1 pathogenesis. Curr HIV/AIDS Rep. 2011;8(1):45–53.
  5. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, et al. Vaccine Immunology (CHAVI). Common genetic variations and the control of HIV-1 in humans. PLoS Genet. 2009;5(12):e1000791.
  6. Smolnikova М. V. Polimorfizm henov tsitokinov v norme i pri VICH-infektsii: [Polymorphism of cytokine genes at normal condition and HIV-infection]. [PhD thesis]. Novosibirsk, 2002. 22 p.
  7. Yamamoto T, Price DA, Casazza JP, Ferrari G, Nason M, Chattopadhyay PK, Roederer M, et al. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.(18): 4805–4815.
  8. Blackburn SD, Wherry EJ. IL-10, T cell exhaustion and viral persistence. Trends Microbiol. 2007;15(4):143–6.
  9. Wang Y, Rice AP. IL-10 inhibits HIV-1 LTR-directed gene expression in human macrophages through the induction of cyclin T1 proteolysis. Virology. 2006;352(2):485–92.
  10. Ketlinskyi SАSimbirtsev ASTsyitokini [Cytokines]. Saint Petersburg: Fp.
  11. Wang C, Song W, Lobashevsky E, WilsonCM, Douglas SD, Mytilineos J, Schoenbaum EE, et alCytokine and chemokine gene polymorphisms among ethnically diverse North Americans with HIV-1 infection. J Acquir Immune Defic Syndr. 2004;35(5):446–54.
  12. Biktagirova EM, Sattarova LI, Vagapova GR, Kravtsova OA[Association of IL-1β, IL-4 and IL-6 genes polymorphisms with genetic predisposition for autoimmune thyroiditis].Meditsinskaya Immunologi 2011;6:603–608.
  13. Jun TY, Lee KU, Pae CU, Chae JH, BahkWM, Kim KS, Han H. Polymorphisms of interleukin-4 promoter and receptor gene for schizophrenia in the Korean population. Psychiatry Clin Neurosci. 2003;57(3):283–8.
  14. Gatlin MR, Black CL, Mwinzi PN,Secor WE,Karanja DM, ColleyAssociation of the gene p patterns of reinfection with Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(2):e375.
  15. Saxena M, Agrawal CC, Bid HK, Banerjee M. An interleukin-10 gene promoter polymorphism (-592A/C) associated with type 2 diabetes: a North Indian study. Biochem Genet. 2012;50(7–59.
  16. Lee YT, Tsai YC, Yang YK, Hsu KT, LiaoSC, Wu CH, Cheng BC, et alAssociation between interleukin-10 gene polymorphism −592 (A/C) and peritoneal transport in patients undergoing peritoneal dialysis. Nephrology (Carlton). 2011;16(7):663–71.
  17. Helmig S, Aliahmadi N, Stephan P, Dhrel J, SchneiderTNF-α -308 genotypes are associated with TNF-α and TGF-β mRNA expression in blood leucocytes of humans.;53(3):306–310.
  18. Lpez-Hernandez R, Valdes M, Campillo JA, Martinez-Garcia P, Salama H, Salgado G, Boix F, Moya-Quiles MR, et alGenetic polymorphisms of tumour necrosis factor alpha (TNF-α) promoter gene and response to TNF-α inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet. 2014;41(1):63–8.
  19. Sobti RC, Berhane N, Mahedi SA, Kler R, Hosseini SA, Kuttiat V, WanchuPolymorphisms of IL-6 174 G/C, IL-10 -592 C/A and risk of HIV/AIDS among North Indian population. Mol Cell Biochem. 2010;337(1–2):145152.

 

 

ASSOCIATION OF K121Q POLYMORPHISM ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPPI) GENE WITH ACUTE CORONARY SYNDROME IN PERSONS OF DIFFERENT SEXES

Authors: Rozymenko I.A. 

Pages: s38-s44

Abstract


Introduction. Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 is an enzyme, which is encoded by the ENPP1 gene in humans. This gene is a member of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family. The encoded protein is a type II transmembrane glycoprotein comprising two identical disulfide-bonded subunits. This protein has broad specificity and cleaves a variety of substrates, including phosphodiester bonds of nucleotides and nucleotide sugars and pyrophosphate bonds of nucleotides and nucleotide sugars. This protein may function to hydrolyze nucleoside 5' triphosphates to their corresponding monophosphates and may also hydrolyze diadenosine polyphosphates. Mutations in this gene have been associated with іdiopathic infantile arterial calcification, ossification of the posterior longitudinal ligament of the spine, insulin resistance. As the calcification of the atherosclerotic plaque is an untoward prognostic factor of the acute coronary syndrome, the polymorphism of gene ENPP1 can be associated with the disease progression.

The aim was to establish the frequency of allelic variants of the ENPPI gene for K121Q polymorphism in patients of different sexes with acute coronary syndrome (ACS).

Material and Methods. We used venous blood of 118 patients with ACS (22 % women and 78 % men) aged 40 to 73 years (mean age 55.9 ± 0.89 years) who were hospitalized in the cardiology department of Sumy City Clinical Hospital № 1. The control group consisted of 110 patients. Definition of K121Q polymorphism (rs1044498) of ENPPI gene was performed using PCR with the following restriction fragment length analysis of the allocation of them by electrophoresis in agarose gel. Restriction endonuclease Eco47I (AvaII) was used for restriction analysis. Statistical analysis was performed using the software package SPSS-17. Thus, the significance of differences was determined by the χ2-criterion. The value of P < 0.05 was considered as significant.

Results. Using the χ2-Pearson criterion, I did not reveal association between the K121Q polymorphism of ENPPI gene and the development of ACS. Distribution of different types of genotype between patients with ACS and healthy patients did not differ statistically significantly. I pointed out that in patients with ACS value homozygotes for the major allele (K/K) and minor allele carriers (K/Q + Q/Q) were 66.9 and 33.1 %, while in the control group –75.5 and 24.5 %, respectively. Factor P, defined by χ2-Pearson criterion, was equal to 0.157 and indicated a lack of significant difference in the distribution of allelic variants of the gene ENPP1 K121Q polymorphism in patients with ACS and the controls.

The value of the given options polymorphism in females was unreliable in patients with ACS and controls (P = 0.280). The distribution of allelic potions K121Q polymorphism in males also did not differ in comparison to patients with ACS and controls (P = 0.320).

Conclusion. There is no link between the polymorphism K121Q of gene ENPP1 and the acute coronary syndrome in males and females.

Key words: ectonucleotide pyrophosphatase/phosphodiesterase, acute coronary syndrome, allelic polymorphism.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

 

  1. Johnson K, Goding J, Van Etten D, Sali A, Hu SI, Farley D, Krug H, et alLinked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res.2003;18(6):994–1004.
  2. Ruf N, Uhlenberg B, Terkeltaub R, NurnbergP, Rutsch F. The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with Generalized Arterial Calcification of Infancy (GACI). Human Mutation. 2005;26(5):495–496.
  3. Rutsch F, Vaingankar S, Johnson K, GoldfineI, Maddux B, Schauerte P, KalhoffH, et alPC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial сalcification. American Journal of Pathology. 2001;158(2):543–554.
  4. Glatz AC, Pawel BR, Hsu DT, Weinberg P, Chrisant MRK. Idiopathic infantile arterial calcification: two case reports, a review of the literature and a role for cardiac transplantation. Pediat Transplant. 2006; 10:225–233.
  5. Nakamura I, Ikegawa S, Okawa A, Okuda S, Koshizuka Y, Kawaguchi H, Nakamura K, et alAssociation of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL). Hum Genet. 1999;104(6):492–497.
  6. Pizzuti A, Frittitta L, Argiolas A, Baratta R,. Goldfine ID, Bozzali M, Ercolino T, et alA p Diabetеs. 1999; 48(9):1881–1884.
  7. Bacci S, Ludovico O, Prudente S, Zhang Y-Y, Di Paola R, Mangiacotti D, Rauseo A, et alThe K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier оnset of type 2 diabetes and myocardial infarction. Diabetеs. 2005; 54(10):3021–3025.
  8. Meyre D, Bouatia-Naji N, Vatin V, Veslot J, Samson C, Tichet J, Marre M, et alENPP1 K121Q polymorphism and obesity, hyperglycaemia and type 2 diabetes in the prospective DESIR Study. Diabetologia. 2007;50:2090–2096.
  9. El Achhab Y, Meyre D, Bouatia-Naji N, Berraho M, Deweirder M, Vatin V, Delplanque J, et alAssociation of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population. Diabetes Metab. 2009;35(1):37–42.
  10. Lee JE, Choi YK, Seo HA, Jeon JH, Jeong JY, Moon SS, Kim JG, et alImpact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population.Diabetes Res Clin Pract. 2010;88(1):87–96.
  11. Cte N, El Husseini D, Pepin A, Guauque-Olarte S, Ducharme V, Bouchard-Cannon P, Audet A, Fournier D, et al.ATP acts as a survival signal and prevents the mineralization of aortic valve. J Mol Cell Cardiol. 2012;52(5):1191–202.
  12. Moehlecke M, Kramer KC, Cristiane B, KraheAL, Balbosco I, de Azevedo JM, Gross JL, Canani LH. ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients. Arq Bras Cardiol. 2010;94(2):157–161.
  13. Eller P, Schgoer W, Mueller T, Tancevski I, Demetz E, Duwensee K, Ritsch A, et alThe K121Q polymorphism of ENPP1 and peripheral arterial disease. Heart Vessels. 2008;23(2):104–107.
  14. Wang RQ, Zhou DH, Xi B, Ge XS, Zhu P, Wang B, Zhou MA, etalENPP1/PC-1 gene K121Q рolymorphism іs аssociated with оbesity in European аdult p Biomed Environ Sci. 2011;24(2):200–206.
  15. Gonzalez-Sanchez JL, Zabena C, Martinez-Larrad MT, Martinez-Calatrava MJ, Perez-Barba M, Serrano-Ríos M. Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome. Clin Endocrinol. 2008;68(5):724
  16. Suk EK, Malkin I, Dahm S, Kalichman L, RufN, Kobyliansky E, Toliat M, et alAssociation of ENPP1 gene polymorphisms with hand osteoarthritis in a Chuvasha population. Arthritis Res Ther. 2005;7(5): R1082–1090.
  17. Baba T, Endo T, Sata F, Honnma H, KitajimaY, Hayashi T, Manase K, et alPolycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci. 2007;81(10):850–854.
  18. Takahama Y, Uto H, Kanmura S, Oketani M, Ido A, Kusumoto K, Hasuike S, et alAssociation of a genetic polymorphism in ectonucleotide pyrophosphatase/phosphodiesterase 1 with hepatitis C virus infection and hepatitis C virus core antigen levels in subjects in a hyperendemic area of Japan. J Gastroenterol. 2008;43(12):942–950.
  19. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, et alAutosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 g Am J Hum Genet. 2010;86(2):273–8.
  20. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, et alACC/AHA guidelinesfor the management of patients with unstable angina and non ST-elevation myocardial infarction: executive summary and recommendations. A report of the american college of cardiology. Circulation. 2000;102:1193–1209.
  21. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809–1840.
  22. Chen MP, Chung FM, Chang DM, Tsai J, Huang HF, Shin SJ, Lee YJ. ENPP1 K121Q Polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese Population. Rev Diabet Stud. 2006;3(1):2130.

 

 

CONNECTION OF BCL1 POLYMORPHISM OF GLUCOCORTICOIDS RECEPTOR GENE WITH SEVERITY OF COURSE AND OBESITY PATIENTS WITH BRONCHIAL ASTHMA

Authors: Kmyta V.V.

Pages: s45-s51

Abstract


The purpose of our investigation was study the connection between Bcl1 polymorphism of glucocorticoids receptor gene (GR) with severity of course of disease and obesity patients with bronchial asthma (BA).

188 patients with BA and 95 almost healthy patients were examined. Body mass index, the pulmonary function test (PFT)were investigated. Determination of Bcl1 polymorphism of 2d glucocorticoids receptor exongene (GR) performed with FleuryI. etal. method with modifications. Statistically results processing were done with using of the SPSS-17programs.

The results of analyses of the genotype distribution by Bcl1 polymorphism GR gene dependingon severity of BA course showed that C/C genotype associated with easy course of disease, meanwhile, G/G with severe course. The analyzes of distributing allelic variations GR depending onforced expiratory volume in 1 second (FEV1)  showed more expressed obstructive changes in minor allele carries (C/G+G/G) comparing with homozygotes by main allele. We pointed out that patients with BA with C/C genotype index FEV1 showed 68.6 (95% CI 64.9–7.3), and with G/G genotype – 59.9(95% CI 57.02–62.7).

The analysis of genotype distribution by Bcl1 polymorphism GR gene depending on the level FEV1 with consideration BMI showed that genotype C/C mostly occured in patients with normal body mass and FEV1 in normal limits and in range of 60–80% from appropriate values, and genotype G/G –in patients with obesity and severe disorders FEV1.

Obtained results proved the availability of connection between genotypes by Bcl1 polymorphism GR gene, BMI and degree of disorder PFT in patients with BA.

Key words: bronchial asthma, Bcl1 polymorphism, body mass index, the degree of severity.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

 

  1. Belevskii АS. Globalnaya strategiia lecheniia i profilaktitki bronkhialnoi astmy (peresmotr  2011 g.) [Global strategy for the treatment and prevention of bronchial asthma (Review 2011)]. М: Rosiiskoe respiratornoie obshchestvo Publ., 2012. 108 p.
  2. Lenzer J. Obesity related illness consumes a sixth of US health care budget. BMJ. 2010;341:c
  3. Boulet LP. Asthma and obesity. Clin Exp Allergy. 2013 Jan;43(1):8–21.
  4. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol. 2005;115(5):897–909.
  5. Kajbaf TZ, Asar S, Alipoor MR. Relationship between obesity and asthma symptoms among childrenin Ahvaz, Iran: a crosssectional study. Italian Journal of Pediatrics2011;37:1.
  6. Saint-Pierre P, Bourdin A, Chanez P, DauresJP, Godard P.Are overweight asthmatics more difficult to control? 2006;61(1):79–84.
  7. Peters-Golden M, Swern A, Bird SS, HustadCM, Grant E, Edelman JM.Influence of body mass index on the response to asthma controller agents. Eur Respir J. 2006;27(3):495–503.
  8. Sutherland ER, Goleva E, Strand M, BeutherDA, Leung DY.Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682–7.
  9. Hallstrand TS, Fischer ME, Wurfel MM, AfariN, Buchwald D, Goldberg JGenetic pleiotropy between asthma and obesity in a community-based sample of twins. J Allergy Clin Immunol. 2005;116(6):1235–41.
  10. Akerman MJH, Calacanis CM, Madsen MK. Relationship between asthma severity and obesity. J Asthma. 2004;41(5):521–526.
  11. Mosen DM, Schatz M, Magid DJ, CamargoCA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol. 2008;122(3):50711.e6.
  12. Tantisira K, Weiss S. The pharmacogenetics of asthma treatment. Curr Allergy Asthma Rep. 2009;9(1):10–17.
  13. van Rossum EF, Koper JW, vandenBeldAW, Uitterlinden AG, Arp P, Ester W, Janssen JA, et al.Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol (Oxf). 2003;59(5):585–92.
  14. Pietras T, Panek M, Tworek D,Oszajca K, Wujcik R, Grski P, Kuna P, SzemrajThe BclI single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. Mol Biol Rep. 2011;38(6):3953–3958.

 

 

COMPUTED TOMOGRAPHY CHANGES OF THE BRAIN IN PATIENTS WITH TRAUMATIC BRAIN INJURY AND THEIR DEPENDENCE ON THE -675 4G/5G POLYMORPHISM IN THE PAI-1 GENE

Authors: Potapov O.O., Kmyta O.P.

Pages: s52-s57

Abstract


Secondary changes in the brain that occur during the early posttraumatic period remain a major cause of death in patients with severe traumatic brain injury. The purpose of our study was to analyze brain changes over time in patients with severe traumatic brain injury studying the association between the results of computed tomography examinations and the -675 4G/5G polymorphism in the PAI-1 gene.

We examined 119 patients with severe traumatic brain injury. Computed tomography changes of brain tissues in patients with severe traumatic brain injury were investigated. Determination of the -675 4G/5G polymorphism in the PAI-1 genewas performed. Statistical processing of the results was done with programsSPSS-17.

We found an association between posttraumatic computed tomography changes of brain tissues in patients with severe traumatic brain injury and the genotypes for the -675 4G/5G polymorphism in the PAI-1 gene: namely, more evident and accelerated involution of lesions in patients with 5G/5G genotype; more rapid recovery in patients with 4G/4G genotype; confirmed predisposition to developing secondary complications, pathological lesions evolution in the brain, and secondary ischemic complications in patients with 4G/5G genotype for the investigated polymorphism.

The obtained results proved the availability of connection between genotypes -675 4G/5G polymorphism in the PAI-1 gene, secondary complications, pathological lesions evolution in the brain, and secondary ischemic complications in patients with severe traumatic brain injury.

Key words: traumatic brain injury, computed tomography examination of the brain, the -675 4G/5G polymorphism in the PAI-1 gene.

This email address is being protected from spambots. You need JavaScript enabled to view it.

The full text

To view the full text

References

  1. Bruns J Jr, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia. 2003;44(Suppl 10):2–10.
  2. Huk АP. [TBI epidemiology in Ukraine]. Epidemiologia cherepno-mozkovoi travmy v Ukraini [Proceedings of the V Congress of Ukrainian Neurosurgeons]. Uzhorod, 2013, p.38. (In Ukrainian).
  3. Lekhan VМ, Huk АP. [Specifics of traumatic brain injury epidemiology in Ukraine]. Ukrayina. Zdorovia natsii. 2010;2:7–14.
  4. Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW.Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and computed tomographic predictors. 2005;57(6):1173–82.
  5. Huq MA, Takeyama N, Harada M, Miki Y, Takeuchi A, Inoue S, Nakagawa T, Kanou H, et al.4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene is associated with multiple organ dysfunction in critically ill patients. Acta Haematol. 2012;127(2):72–80.
  6. Genet GF, Johansson PI, Meyer MA, SlbeckS, Srensen AM, Larsen CF, WellingKL, et al. Trauma-induced coagulopathy: standard coagulation tests, biomarkers of coagulopathy, and endothelial damage in patients with traumatic brain injury. J Neurotrauma. 2013;30(4):301–306.
  7. Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G.The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res. 2008;122(6):736–742.
  8. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, et al.The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost. 2006;96:471–477.
  9. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost. 2005;93(4):631–640.
  10. Wiklund PG, Nilsson L, Ardnor SN, ErikssonP, Johansson L, Stegmayr B, Hamsten A, et alPlasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 2005;36(8):1661–1665.
  11. Sirko АH. [Clinical and CT features of severe TBI]. Patolohia. 2011;8(3):85–89.
  12. Trufanov HЕ, Ramishvili ТЕ. Luchevaia diagnostika travm golovy i pozvonochnika: rukovodstvo dlia vrachei [X-ray diagnostics of head and spinal cord injuries: manual for physicians]. SPb.: ELBI-SPb Publ., 2007. 196p.

 

LIPID PROFILE AND LEVEL OF INFLAMMATORY MARKERS IN PATIENTS WITH CORONARY HEART DISEASE DEPENDING ON Ɛ4-ALLELE CARRIER Ɛ2/Ɛ3/Ɛ4-GENE POLYMORPHISM OF LIPOPROTEIN E

Authors: Prystupa L.N., Psarova O.V.

Pages: s58-s65

Abstract


Our aim was to investigate the level of blood lipids and inflammatory markers in patients with coronary artery disease (CAD) depending on carrier ɛ4-allele ɛ2/ɛ3/ɛ4-apolipoprotein E gene polymorphism.

Material and Methods. The study involved 150 patients with CAD. Gene polymorphism of apolipoprotein E studied by Hixson et. al. (1990). DNA was extracted from whole blood using the sets DIAtom DNA Prep 100 («Isogene», Russia). rs7412 and rs429358 polymorphisms exon 4 was determined by polymerase chain reaction followed by restriction fragment length analysis. We performed enzymatic colorimetric method using a set of reagents "Olveks diagnosticum" (Russia) in accordance with the manufacturer's methods to study total cholesterol, HDL and TG. We identified CRP, IL-6 and TNF-α to assess the presence of systemic inflammatory response of the body. Their quantitative assessment was performed using the kits JSC "VECTOR-BEST" (Russia) and by enzyme immunoassay technique according to the manufacturer. Processing of the results was performed using the statistical analysis package SPSS 17.0

Results. Analysis of the genetic polymorphism of apoE showed that among 150 patients with CAD carriers ɛ4-allele were 37 (24.7%) patients, whereas no carriers – 113 (75.3%). We established that carriers ɛ4-allele were mostly men 28 (75.7%), while women – 9 (24.3%); statistically significant differences in Pearson χ2 criterion were found (p = 0.566). We found that in patients who are not carriers of allele frequency ɛ4-hypertension, SBP and DBP levels were significantly higher compared with native ɛ4-allele (p = 0.007, 0.058, 0.03, respectively). The analysis of HDL levels in patients with CAD depending on carrier ɛ4-allele showed that patients who are carriers of ɛ4-allele HDL was significantly lower compared with non-carriers ɛ4-allele (p = 0.013). Atherogenic index (AI) was significantly higher in patients who are carriers ɛ4-allele compared with non-carriers ɛ4-allele (p = 0.006). Patients who are carriers ɛ4-allele had higher levels of CRP and IL-6, but statistically significant differences in the Pearson χ2 criterion were found (p = 0.295, 0.492, respectively).

Conclusion. ɛ4-allele carriers have higher levels of blood lipids and inflammatory markers, indicating the progression of atherosclerosis.

Key words: coronary heart disease, apoE gene polymorphism, lipid profile, inflammatory markers.

psaryova@mail.ru

The full text

To view the full text

References

  1. Derzhavna sluzhba statystyky Ukrainy [State Statistics Service of Ukraine]. Retrieved from: http://www.ukrstat.gov.ua/
  2. Kovalenko VM, Kornatskyi VM, editors. Dynamika stanu zdorovia narody Ukrainy ta rehionalni osoblyvosti. Analitychno-statystychnyi posibnyk [Dynamics of health status of Ukrainian population and regional features. Statistic and analytic manual]. Кyiv, 2012. 211 p.
  3. Boiko ER, Kanaeva AM. [Apolipoprotein E and its value in clinical physiology]. Uspekhi Phisiol Nauk. 2009;40(1):3–15. 
  4. Pavlenko MA, Bairamukova AA, Alibaeva NT, Dronov DA, Mirakhimov EM. [The role of apolipoprotein E gene polymorphism in the development of atherosclerosis (review)]. Vestnik 2007;7(9):32–35.
  5. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. 2007;298(11):1300–1311.
  6. Hagberg JM, Kennet KR, Ferrell RE. APO E gene and gene-enviromental effects on plasma lipoprotein-lipid levels. Physiol Genomics. 2004;4(2):1011–08.
  7. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, Kesaniemi YA, Faergeman O. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101(12):1366–1371.
  8. Chiodini BD, Franzosi MG, Barlera S, Signorini S, Lewis CM, D'Orazio A, Mocarelli P, et al.Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. Eur Heart J. 2007;28(16):1977–1983.
  9. Song Y, Stampfer VJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141(2):137–47.
  10. Eiriksdottir G, Aspelund T, Bjarnadottir K, Olafsdottir E, Gudnason V, Launer LJ, Harris TB.Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES-Reykjavik Study. 2006;186(1):222–4.
  11. Khashimov ShU, Bekmetova FM, Akhmedova ShS, Shek AB,Kurbanov RD. [The specific features of lipid profile and inflammation markers in patients with unstable angina depending on apolipoprotein E gene polymorphism]. Profilac Medicine2011; 14(1):16–18.